Francisco Hernandez-Ilizaliturri MD
Hematologic Oncology
Director of the Lymphoma Research, Head of the Lymphoma Translational Research Program, Professor of Medical Oncology, Department of Medicine, Roswell Park Cancer Institute. Associate Professor of Medicine, SUNY Buffalo School of Medicine and Biomedical Sciences
Join to View Full Profile
Elm And Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-3894
Dr. Hernandez-Ilizaliturri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002- University at BuffaloResidency, Internal Medicine, 1996 - 1999
Escuela de Medicina Ignacio A. SantosClass of 1995
Certifications & Licensure
NY State Medical License 2009 - 2026
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2011 Dec 06
- Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Start of enrollment: 2007 Apr 17
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis
Journal of the National Comprehensive Cancer Network. 2025-10-01 - 1 citationsCarfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 s...Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh
Leukemia & Lymphoma. 2025-09-01 - 1 citationsLisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM S...Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Journal of Clinical Oncology. 2025-08-20
Abstracts/Posters
- Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCLFrancisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT EraFrancisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)Clinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-cell Lymphomas? New Insights at ASHDecember 9th, 2024- Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic LeukemiaDecember 7th, 2024
- Castle Connolly Names 38 Roswell Park Physicians to ‘Top Doctors’ ListFebruary 2nd, 2023
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
